Kazuhiro Kawamura1, Nanami Kawamura, Aaron J W Hsueh. 1. aDepartment of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan bDepartment of Obstetrics/Gynecology, Stanford University School of Medicine, Stanford, California, USA.
Abstract
PURPOSE OF REVIEW: Premature ovarian failure (POF) is diagnosed by amenorrhea before 40 years of age. Owing to exhaustion of follicles in POF ovaries, egg donation is the only option. Although menstrual cycles cease in POF patients, some of them still contain residual dormant follicles in ovaries. Recently, we developed a new infertility treatment and named it as in-vitro activation (IVA), which enables POF patients to conceive using their own eggs by activation of residual dormant follicles. Here, we summarize data showing the potential of IVA as a new infertility treatment for POF patients. RECENT FINDINGS: Transgenic mouse studies revealed that the stimulation of phosphatidylinositol-3-kinase-AKT-forkhead box O3 pathway activated dormant primordial follicles. In murine and human ovaries, the phosphatase and tensin homolog inhibitors and phosphatidylinositol-3-kinase activators were demonstrated to activate dormant primordial follicles in in-vitro cultures. Subsequent studies showed that ovarian fragmentation suppressed Hippo signaling pathway, leading to ovarian follicle growth. Combining these two methods in an IVA approach followed by ovarian tissue autotransplantation, successful follicle growth, and pregnancies were reported in POF patients. Currently, two healthy babies were delivered, together with two additional pregnancies. SUMMARY: IVA treatment is a potential infertility therapy for POF patients who have residual follicles.
PURPOSE OF REVIEW: Premature ovarian failure (POF) is diagnosed by amenorrhea before 40 years of age. Owing to exhaustion of follicles in POF ovaries, egg donation is the only option. Although menstrual cycles cease in POFpatients, some of them still contain residual dormant follicles in ovaries. Recently, we developed a new infertility treatment and named it as in-vitro activation (IVA), which enables POFpatients to conceive using their own eggs by activation of residual dormant follicles. Here, we summarize data showing the potential of IVA as a new infertility treatment for POFpatients. RECENT FINDINGS: Transgenic mouse studies revealed that the stimulation of phosphatidylinositol-3-kinase-AKT-forkhead box O3 pathway activated dormant primordial follicles. In murine and humanovaries, the phosphatase and tensin homolog inhibitors and phosphatidylinositol-3-kinase activators were demonstrated to activate dormant primordial follicles in in-vitro cultures. Subsequent studies showed that ovarian fragmentation suppressed Hippo signaling pathway, leading to ovarian follicle growth. Combining these two methods in an IVA approach followed by ovarian tissue autotransplantation, successful follicle growth, and pregnancies were reported in POFpatients. Currently, two healthy babies were delivered, together with two additional pregnancies. SUMMARY:IVA treatment is a potential infertility therapy for POFpatients who have residual follicles.
Authors: M Méndez; F Fabregues; J Ferreri; J M Calafell; A Villarino; J Otero; R Farre; F Carmona Journal: J Assist Reprod Genet Date: 2022-07-29 Impact factor: 3.357
Authors: Robert T Rydze; Bethany K Patton; Shawn M Briley; Hannia Salazar Torralba; Gregory Gipson; Rebecca James; Aleksandar Rajkovic; Thomas Thompson; Stephanie A Pangas Journal: Biol Reprod Date: 2021-11-15 Impact factor: 4.161